Prescribing
Information
DARZALEX FASPRO®DARZALEX®
This site is intended for US healthcare professionals.
Prescribing Information
DARZALEX FASPRO®DARZALEX®
Get in Touch
Dosing & Administration Guide
DARZALEX FASPRO®DARZALEX®
Support & Resources
Expert VideosMOAAdditional RegimensNCCN GuidelinesPractice SupportPatient Support & Resources
Get in Touch
FAQs
Patient Site
MM Portfolio
For APPs & Nurses
For APPs
& Nurses
Explore a DRd
Regimen
Discover a DVRd
Regimen
Continuous
Treatment
  • CHOOSE REGIMEN
    Explore a DRd
    Regimen
    Explore a DRd RegimenDiscover a DVRd RegimenContinuous Treatment
  • MAIA: DRd in
    Transplant-Ineligible
    NDMM
    MAIA Study
    Design
    Proven EfficacyDemonstrated
    Safety Profile
    Dosing
  • Exploratory
    Subgroup
    Analyses
    High-Risk
    Subgroup
    Frailty
    Subgroup
    Age
    Subgroup
Prescribing
Information
DARZALEX FASPRO®DARZALEX®
This site is intended for US healthcare professionals.
Prescribing Information
DARZALEX FASPRO®DARZALEX®
Get in Touch
Dosing & Administration Guide
DARZALEX FASPRO®DARZALEX®
Support & Resources
Expert VideosMOAAdditional RegimensNCCN GuidelinesPractice SupportPatient Support & Resources
Get in Touch
FAQs
Patient Site
MM Portfolio
For APPs & Nurses
Go to DARZALEX® (daratumumab) & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) HCP homepageGo to DARZALEX® (daratumumab) & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) HCP homepage
Check IconNOW
APPROVED

DARZALEX FASPRO® + VRd is approved in transplant-ineligible patients with newly diagnosed multiple myelomaNDMM1

DARZALEX FASPRO® monotherapy is the first and only FDA-approved treatment in high-risk smoldering multiple myeloma1DARZALEX FASPRO® monotherapy is now approved in high-risk smoldering multiple myeloma1